Evidence map›Paper›PMID 29712650›Full record

ArticleAntimicrobial agents and chemotherapy2018

Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in

Wafi Siala, Hector Rodriguez-Villalobos, Prabhavathi Fernandes, Paul M Tulkens, Françoise Van Bambeke

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Mechanisms of fusidic acid resistance.Biochemical Society transactions · 2025
    Review
  2. Review
  3. Article
  4. DynamicAntibiotics (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Life (Basel, Switzerland) · 2020
    Article
  12. Rifabutin Use inAntibiotics (Basel, Switzerland) · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Activity of Antibiotics against Staphylococcus aureus in anAntimicrobial agents and chemotherapy · 2019
    Article
  18. Role of Rifampin against Staphylococcal Biofilm InfectionsAntimicrobial agents and chemotherapy · 2019
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Wafi SialaPharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Hector Rodriguez-VillalobosLaboratoire de microbiologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
Prabhavathi FernandesCempra, Inc., Chapel Hill, North Carolina, USA.
Paul M TulkensPharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.ORCID 0000-0002-7121-3623
Françoise Van BambekePharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium francoise.vanbambeke@uclouvain.be.ORCID 0000-0002-0052-7991
UCLouvain · BECempra Pharmaceuticals (United States) · USCliniques Universitaires Saint-Luc · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcal biofilms are a major cause of therapeutic failure, especially when caused by multiresistant strains. Oral fusidic acid is currently being redeveloped in the United States for skin, skin structure, and orthopedic infections, in which biofilms play a major role. The aim of this study was to examine the activity of fusidic acid alone or combined with other antistaphylococcal drugs against biofilms made by a reference strain and five clinical isolates of

Indexed as

Anti-Bacterial AgentsBiofilmsDaptomycinFusidic AcidHumansMicrobial Sensitivity TestsMoxifloxacinRifampinStaphylococcus epidermidisAnti-Bacterial AgentsDaptomycinFusidic AcidMoxifloxacinRifampinbiofilmCDC biofilm reactordaptomycinfusidic acidlinezolidStaphylococcus aureusStaphylococcus epidermidis

Identifiers

PMID29712650
PMCPMC6021669
OpenAlexW2800223684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.